In a primary analysis, PLUVICTO reduced the risk of cancer worsening by an additional 28% vs hormone therapy alone.¹

50% of men on hormone therapy alone lived without cancer worsening for 48.5 months while men on PLUVICTO lived longer than that without cancer worsening (the exact length of time is continuing to be measured).²

In the PSMAddition clinical study, PLUVICTO was given once every 6 weeks for a total of 6 doses. 572 men received PLUVICTO plus hormone therapy and 572 men received hormone therapy alone.¹

Initial analysis results numerically favored men taking PLUVICTO plus hormone therapy to live longer vs men taking hormone therapy alone. These results were not statistically significant, and it is too early to make any conclusions about the survival analysis to support a difference between PLUVICTO plus hormone therapy vs hormone therapy alone.²

Percentage of men who had tumors shrink or disappear²

This result is called the overall response rate (ORR),^† which is calculated by adding complete response (CR), which is when a tumor disappears, and partial response (PR), which is when a tumor shrinks.⁷

• CR: 63% with PLUVICTO plus hormone therapy vs 49% with hormone therapy alone²

• PR: 23% with PLUVICTO plus hormone therapy vs 32% with hormone therapy alone²

*Hormone therapy included a combination of testosterone-lowering treatment called androgen deprivation therapy (ADT) and testosterone receptor blocker treatment called androgen receptor pathway inhibitor (ARPI).^1,5,8

^†Measuring ORR was not the main goal of the PSMAddition clinical study.¹ This finding is not statistically significant and does not impact the results related to cancer worsening.

Percentage of men who had undetectable PSA (<0.2 ng/mL) at nearly 1 year (48 weeks)²

*These men had already received hormone therapy for mPC.¹

^†Additional analysis conducted to learn more about rPFS in PLUVICTO patients.

The PSMAfore clinical study measured rPFS.¹ Median rPFS is the time when half of the men in the study were still alive without their cancer getting worse.^10,11

This clinical study included men previously treated with hormone therapy. PSMAfore included 468 men with PSMA+ prostate cancer that spread outside their prostate. They were divided into 2 groups¹:

• 234 men were treated with PLUVICTO 

  • PLUVICTO was given once every 6 weeks for up to 6 treatments 

• 234 men were treated with a second hormone therapy

Median overall survival (OS) was higher in patients who had PLUVICTO (24.5 months) vs patients on a second hormone therapy (23.1 months). These results were not statistically significant.¹

With PLUVICTO, more men had a tumor response¹

Even if scans don’t show shrinkage or disappearance of tumors, PLUVICTO can still help by slowing the cancer down and giving you more time. In the study, PLUVICTO helped many people by keeping their disease stable, even if the tumors didn’t shrink or disappear.¹²

This result is called the overall response rate (ORR),^‡ which is calculated by adding complete response (CR), which is when a tumor disappears, and partial response (PR), which is when a tumor shrinks.⁷

• CR: 21% with PLUVICTO vs 2.8% with a second hormone therapy¹

• PR: 28% with PLUVICTO vs 11% with a second hormone therapy¹

^‡Measuring ORR was not the main goal of the PSMAfore clinical study.¹ This finding is not statistically significant and does not impact the results for rPFS.

If PSA was 100 ng/mL before the clinical study, then PSMAfore would measure the PSA level if it dropped to 50 ng/mL or lower.⁹

^§Measuring PSA response was not the main goal of the PSMAfore clinical study.⁹ This finding is not statistically significant and does not impact the results for rPFS.

Watch a patient and doctor share their perspectives on starting PLUVICTO.^||

^||Patient and health care provider experiences are individual and vary. Rick and Dr Beckermann were compensated for their participation in this video.

The VISION clinical study measured OS.¹ Median OS is the length of time half of the men in the study were still alive.¹³

Results have been rounded from 15.3 to 15 months and 11.3 to 11 months.¹

This clinical study included men previously treated with hormone therapy and chemotherapy. VISION included 831 men with PSMA+ prostate cancer that spread outside their prostate. They were divided into 2 groups¹:

• 551 men were treated with PLUVICTO plus standard therapy*

  • PLUVICTO was given once every 6 weeks for up to 6 treatments  

• 280 men were treated with standard therapy alone

^*Standard therapy was chosen by a doctor from among existing approved treatments and did not include chemotherapy, immunotherapy, systemic isotopes like radium-223 (²²³Ra), or drugs still being studied.¹⁴
 

The VISION clinical study measured rPFS.¹ Median rPFS is the time when half of the men in the study were still alive without their cancer getting worse.^10,11†

Results have been rounded from 8.7 to 9 months and 3.4 to 3.5 months.¹⁴ 

^†rPFS results may be misread. In the clinical study, many patients treated with standard therapy alone dropped out early.¹

This result is called the overall response rate (ORR), which is calculated by adding complete response (CR), which is when a tumor disappears, and partial response (PR), which is when a tumor shrinks.⁷

• CR: 9% with PLUVICTO vs 0% with standard therapy¹ 

• PR: 40% with PLUVICTO vs 1.6% with standard therapy¹

If PSA was 100 ng/mL before the clinical study, then VISION would measure the PSA level if it dropped to 50 ng/mL or lower.¹⁶

^‡Measuring PSA response was not the main goal of the VISION clinical study.¹⁴ This finding is not statistically significant and does not impact the results for OS or rPFS.

Hear 2 health care professionals discuss the PLUVICTO treatment experience.^§

^§Health care provider experiences are individual and vary. Dr Koneru and Autumn Jones were compensated for their participation in this video.